The new technology, GoT-Multi, is a formidable leap beyond its predecessor, enabling the simultaneous detection of numerous gene mutations while also monitoring the transcriptomic activity within the same individual cells. By overcoming prior limitations—most notably the inability to analyze formalin-fixed, paraffin-embedded (FFPE) pathology samples—GoT-Multi vastly expands the scope of cancer specimens accessible for in-depth study. These FFPE samples constitute an immense archive in clinical pathology departments worldwide, encapsulating invaluable clinical history that has largely been inaccessible with single-cell multi-omics methods until now.

The significance of GoT-Multi was powerfully illustrated through its application to chronic lymphocytic leukemia (CLL), a typically indolent blood cancer that can undergo a dramatic and often fatal transformation into a highly aggressive lymphoma subtype, known as Richter Transformation. The research team applied GoT-Multi to tens of thousands of individual malignant cells from patient tissue samples, identifying more than two dozen specific gene mutations within single cells and concurrently mapping their gene expression profiles. This dual-layered approach provided a comprehensive view of how mutational changes intersect with cellular behaviors—such as proliferative activity and inflammatory responses—during malignant progression.

This capability to dissect tumor heterogeneity at an extraordinary resolution unveils the dynamic cellular states within evolving cancers. Cells exhibiting hyperproliferation or inflammatory phenotypes were readily classified and correlated to their genetic alterations, revealing pathways involved in treatment resistance and aggressiveness. The implications of understanding these cellular subpopulations are profound, offering potential biomarkers for early detection of transformation events and rational targets for therapeutic intervention that precisely address the malignant subclones resistant to conventional therapies.

The development of GoT-Multi was spearheaded by Dr. Anna Nam, whose leadership in pathology and laboratory medicine has established her as a key figure in precision oncology. The tool’s conceptual and technical foundations originated during her postdoctoral tenure under Dr. Dan Landau at Weill Cornell Medicine, a noted expert in cancer genomics. Together, they laid the groundwork for single-cell genotyping integrated with transcriptomics, setting a foundation that GoT-Multi has robustly expanded upon with enhanced mutation detection capacity and sample versatility.

A defining technical advancement of GoT-Multi lies in its multiplexing capacity—allowing researchers to concurrently genotype multiple loci across the genome while capturing the cell’s transcriptomic profile. This multi-omics integration eliminates the need for separate assays, reducing variability and preserving the integrity of biological signals inherent to each cell. The system leverages state-of-the-art sequencing technologies and computational frameworks to accurately phase mutations and interrogate gene expression patterns linked to neoplastic progression and therapeutic escape.

The research consortium’s decision to focus initially on hematologic malignancies, particularly treatment-resistant lymphomas, represents a strategic choice reflecting the urgent clinical need to understand and counteract therapy failure. By applying GoT-Multi to large cohorts of lymphoma biopsies, they aim to systematically profile the cellular ecosystem underlying resistance, potentially uncovering conserved molecular pathways that can be exploited to design next-generation targeted therapies. These investigations also extend to precancerous states, providing a continuum view from early neoplastic lesions through to fully transformed and resistant tumors.

Beyond its scientific and clinical implications, GoT-Multi underscores the power of integrating advanced technological innovation with rich clinical samples to push the boundaries of cancer biology. The ability to study archival FFPE specimens opens vast retrospective research possibilities, linking genetic and transcriptomic alterations to long-term patient outcomes and therapeutic histories. Consequently, this technology offers a transformative platform for longitudinal studies and real-world data integration that were previously unfeasible.

Importantly, the cross-institutional collaboration between Weill Cornell Medicine and the University of Adelaide exemplifies the global synergies necessary for tackling complex biomedical challenges. The synthesis of expertise spanning pathology, molecular biology, oncology, and bioinformatics has yielded a robust tool that not only enhances our mechanistic understanding of cancer transformation but also serves as a beacon for the future of personalized medicine.

The GoT-Multi platform is poised to catalyze a new era of precision diagnostics, providing clinicians with granular insights into tumor evolution and empowering them to tailor interventions based on the unique mutational and transcriptional landscape of a patient’s cancer. As the field moves toward integrating single-cell multi-omics into routine clinical workflows, the translation of these insights holds the promise of improved prognostication, more effective therapies, and ultimately, better patient outcomes.

Looking forward, the research team is expanding the scope of their investigations, applying GoT-Multi across diverse tumor types and exploring its utility beyond oncology, such as in autoimmune diseases and developmental disorders. The adaptability of the platform to various tissue preparations and its scalability positions it as a versatile tool for broad biological and clinical research applications.

In conclusion, GoT-Multi represents a formidable advance in cancer genomics, uniting genotyping and transcriptomics in a single, scalable assay compatible with real-world clinical samples. By illuminating the molecular intricacies of cancer progression and drug resistance at the single-cell level, this technology sets the stage for transformative discoveries and fosters a new paradigm in precision oncology research and patient care.

Subject of Research: Genotyping and transcriptomic profiling of cancer cells using single-cell multi-omics technology to investigate cancer progression and treatment resistance.

Article Title: Cancer Progression Illuminated by New Multi-Omics Tool

News Publication Date: 10-Oct-2025

Image Credits: Courtesy of the Nam Lab

Keywords: Pathology, Cell pathology

Natural killer cells, vital components of the innate immune system, are renowned for their ability to target and destroy malignant cells without prior sensitization. Despite their importance, understanding the nuanced behavior and adaptation of NK cell subsets in the context of CLL, especially after targeted therapies like ibrutinib, has remained elusive. This research bridges that knowledge gap by delivering a nuanced portrayal of NK cell diversity, function, and molecular underpinnings in disease progression and therapy response.

Researchers collected peripheral blood samples spanning a spectrum of clinical stages, including individuals with monoclonal B-cell lymphocytosis (MBL), newly diagnosed CLL (ND-CLL), and those who had undergone ibrutinib treatment achieving complete or partial responses. Additionally, samples from patients suffering from Richter’s syndrome—a highly aggressive transformation of CLL—were included to provide a comprehensive overview of NK cell behavior in varying disease contexts. This heterogeneous sample set allowed for an in-depth comparative analysis of NK cell subset evolution.

The team harnessed single-cell RNA sequencing technologies to profile the transcriptomes of individual NK cells extracted from patient blood samples. This granular approach enabled precise identification of cellular subsets, their gene expression patterns, and the dynamic shifts occurring in response to therapeutic intervention. Furthermore, the researchers implemented pseudotemporal analysis — a computational technique that orders cells along an inferred developmental or differentiation trajectory — to elucidate the temporal dynamics and lineage relationships of NK cell subsets post-ibrutinib.

Three distinct NK cell subsets emerged from this exhaustive profiling: CD56^bright NK cells, typically associated with immune regulation and cytokine production; CD56^dim NK cells, known for their cytotoxic prowess; and a novel, highly cytotoxic subset uniquely enriched in CLL patients, designated as CLL_NK cells. This newly characterized CLL_NK subset demonstrated a pronounced gene expression signature indicative of specialized functional roles, setting it apart from conventional NK populations.

To uncover crucial genes driving the biology of the CLL_NK subset, the authors employed Mendelian randomization and genomic colocalization analyses—statistical genetics methods that integrate genetic association data to infer causality and pinpoint gene-trait linkages. Such analyses yielded a core set of key genes underpinning the function and expansion of the CLL_NK compartment, thereby illuminating molecular targets with potential therapeutic relevance.

Capitalizing on the discovery of these core genes, the researchers developed a novel cell subset-specific index, termed the CLL_NK Index (CNI), designed to quantify and predict patient responses to immunotherapy. This index not only reflects the abundance and activity of the CLL_NK subset but also serves as a biomarker framework for stratifying patients based on predicted treatment outcomes, thus promising improved personalized therapy.

Beyond genetic profiling, a battery of immune infiltration algorithms were applied to assess the interplay between NK subsets and the broader immune microenvironment within CLL. This integrative analysis uncovered complex regulatory networks and highlighted the critical influence of the CLL_NK subset in modulating immune surveillance and evasion mechanisms, which are pivotal challenges in effective leukemia treatment.

To propel translational potential, the study incorporated drug sensitivity assays combined with molecular docking simulations, aiming to identify compounds capable of modulating NK cell activity or directly targeting malignant B cells. This comprehensive pipeline highlighted semaxanib and ulixertinib as promising candidates, enriching the therapeutic arsenal against CLL. Semaxanib, primarily an angiogenesis inhibitor, and ulixertinib, an ERK1/2 kinase inhibitor, may synergistically augment immune-mediated clearance of leukemic cells by optimizing NK cell functionality.

Crucially, this work underscores the dynamic plasticity of NK cell populations under the selective pressure of ibrutinib therapy. The expansion and functional recalibration of the CLL_NK subset reflect adaptive immune remodeling, which can either facilitate therapeutic success or contribute to resistance mechanisms. Understanding this delicate balance offers new avenues to enhance the efficacy of existing treatments or design novel immunomodulatory strategies.

Moreover, the single-cell transcriptomic approach adopted provides an unprecedented resolution into cellular heterogeneity, unveiling fine-grained molecular features that bulk RNA sequencing methods often obscure. This technological advancement illuminates the complexity of immune cell landscapes in cancer and exemplifies the potential of precision immunology to revolutionize clinical oncology, particularly in indolent but treatment-resistant malignancies like CLL.

The implications of these findings are profound. By mapping NK cell behaviors, identifying key genetic drivers, and linking these elements to clinical outcomes, the study sets the stage for integrating NK cell signatures into routine prognostic and therapeutic frameworks. Such integration heralds a future where monitoring immune cell subsets could guide real-time treatment decisions, tailoring interventions to the evolving immune milieu within individual patients.

Importantly, this research also signals the vital need to consider immune system components beyond the traditionally studied T and B lymphocytes. NK cells, often underappreciated in the context of CLL, now emerge as pivotal players capable of influencing disease course and therapeutic responsiveness. Unlocking their full potential could transform the landscape of immunotherapy for hematologic cancers.

As the field moves forward, further studies are needed to validate the CNI in larger, multicenter cohorts and to explore how modulating the CLL_NK subset might synergize with other treatment modalities, including checkpoint inhibitors and CAR-NK therapies. Such efforts could amplify anti-leukemic immune responses, minimizing relapse and improving long-term survival.

In summary, this landmark research unravels the complex NK cell subset dynamics and their molecular circuits following ibrutinib therapy in CLL, charting a path toward more refined, immune-informed therapeutic strategies. It illuminates the promise of integrating advanced single-cell analyses with genetic epidemiology and computational drug screening to revolutionize cancer care.

Subject of Research: Investigation of NK cell subsets and specific gene signatures dynamics post-ibrutinib therapy in chronic lymphocytic leukemia using single-cell transcriptomics.

Article Title: Unravelling NK cell subset dynamics and specific gene signatures post-ibrutinib therapy in chronic lymphocytic leukaemia via single-cell transcriptomics

Article References:
Liu, C., Ding, T., Zou, R. et al. Unravelling NK cell subset dynamics and specific gene signatures post-ibrutinib therapy in chronic lymphocytic leukaemia via single-cell transcriptomics. BMC Cancer 25, 745 (2025). https://doi.org/10.1186/s12885-025-14166-0

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14166-0